Gadolinium Lawyers
The gadolinium lawyers at Schlichter, Bogard & Denton are representing individuals who have suffered from Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy (NSF and NFD).
These diseases have been linked to gadolinium based contrast agents used in Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) scans on patients with kidney disease.
Schlichter, Bogard & Denton is a National Leader Among Gadolinium Lawyers
The gadolinium lawyers at Schlichter, Bogard & Denton specialize in gadolinium, NSF/NFD and MRI lawsuits. They are experienced in drug lawsuits against the largest pharmaceutical companies.
Because of our experience and success in litigating complicated dangerous drug cases, Schlichter, Bogard & Denton was selected to be a member of the Gadolinium Plaintiffs’ Steering Committee (PSC). The Gadolinium PSC is a small group of attorneys leading MRI lawsuit and gadolinium litigation nationwide. The Gadolinium PSC is involved in addressing issues relating to the Multi-District Litigation for gadolinium cases.
Contact a Gadolinium Lawyer for a Free Consultation
If you or someone you know has been diagnosed with Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy (NSF and NFD) or have experienced symptoms of these diseases, please contact our gadolinium lawyers for a free consultation. Our gadolinium attorneys are nationally recognized experts on gadolinium lawsuits.
The gadolinium lawyers at Schlichter, Bogard & Denton are accepting cases nationwide. Call us at our toll free number 1-800-873-5297 or use the Gadolinium Case Evaluation Form.
What is Gadolinium?
Gadolinium is a contrast agent solution that is injected into the patient’s body before a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) scan is administered. Gadolinium is a chemical element that was approved for use in MRI scans in 1988 and has been used in multiple studies since that time. Gadolinium is used in order to obtain better views of potential tumors or other conditions or diseases in the body.
However, the use of gadolinium contrast dyes place patients with kidney disease or renal failure at risk for developing Nephrogenic Systemic Fibrosis (NSF). Typically, patients suffering from kidney disease or renal failure who undergo an MRI are subjected to much higher levels of gadolinium than a healthy patient. Patients with kidney disease or renal failure are unable to excrete the toxic levels of gadolinium from their system in a timely fashion, resulting in risk for developing NSF/NFD.
The Brand Names of Gadolinium Contrast Dyes that are the subject of pending gadolinium lawsuits include:
- Omniscan made by GE Healthcare
- OptiMARK made by Mallinckrodt/Tyco Healthcare
- Magnevist made by Bayer/Schering AG/Berlex
- ProHance made by Bracco Diagnostics
- MultiHance made by Bracco Diagnostics
While the Food & Drug Administration approved gadolinium for use in Magnetic Resonance Imaging (MRI), the use of the dye has never been approved for use in Magnetic Resonance Angiography (MRA). MRA is a type of scan that is used for the purpose of providing views of the blood vessels inside the body.
